Genzyme troubles boost Icahn proxy bid

Right now, anything that costs Genzyme a significant amount of money and damages its reputation is a big plus for Carl Icahn. And Icahn had good reason to celebrate the big black eye Genzyme got from yesterday's news that the FDA will return to its Allston Landing facility in Boston and take a bigger role in overseeing its operations, a move that will likely pave the way to a considerable government fine. Report